Alnylam Pharmace. buy KongVestor
Summary
This prediction ended on 03.04.21 with a price of €120.00. The prediction for Alnylam Pharmace. disappointed with a performance of -13.33%. KongVestor has 50% into this predictionAlnylam Pharmaceuticals, Inc. (ALNY) is a biopharmaceutical company focused on the development of RNA interference (RNAi) therapeutics. Its lead drug, ONPATTRO®, is approved by the U.S. FDA for the treatment of adults with polyneuropathy of hereditary transthyretin-mediated (hATTR) amyloidosis. The company is also developing additional RNAi therapeutic candidates for the treatment of a range of diseases, including cancer, cardiovascular disease, and viral infections. With a market capitalization of over $15 billion, Alnylam is one of the largest biotech companies in the world.
Performance without dividends (%)
Name | 1w | 1m | 1y | 3y |
---|---|---|---|---|
Alnylam Pharmace. | -1.761% | -1.761% | -27.386% | 18.653% |
iShares Core DAX® | 1.051% | -1.833% | 12.822% | 15.392% |
iShares Nasdaq 100 | -0.547% | -3.738% | 40.625% | 42.396% |
iShares Nikkei 225® | -1.778% | -8.115% | 16.092% | 0.891% |
iShares S&P 500 | 0.002% | -2.226% | 28.387% | 41.095% |
Comments by KongVestor for this prediction
In the thread Alnylam Pharmace. diskutieren